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Methods: Eligible patients were antiretroviral-naı¨ve with documented weight prior to
EFV start and follow-up viral loads after treatment initiation. Cox regression analyses
evaluated the association between weight and time to first undetectable viral load
(<50 copies/ml) after treatment initiation, and time to viral load rebound (two con-
secutive viral load >50 copies/ml) after initial suppression over 5 years of follow-up.
Recovery of CD4þ cell count was evaluated 6 and 12 months after EFV initiation.
Analyses were stratified by weight (kg) group (I – <55; II – >55, <80 (reference); III –
>80, <85; IV – >85, <90; V – >90, <95; VI – >95).
Results: The study included 19968 patients, of whom 9.1, 68.3, 9.1, 5.8, 3.5, and 4.3%
were in weight groups I–VI, respectively. Overall, 81.1% patients attained virological
suppression, of whom 34.1% subsequently experienced viral load rebound. After
multiple adjustments, no statistical difference was observed in time to undetectable
viral load and virological rebound for heavier individuals compared to their normal-
weight counterparts. Although heaviest individuals had significantly higher CD4þ cell
count at baseline, CD4þ cell recovery at 6 and 12 months after EFV initiation was
comparable to normal-weight individuals.
Conclusion: Virological and immunological responses to initial EFV-containing regi-
mens were not impaired in heavy individuals, suggesting that the standard 600mg EFV
dosage is appropriate across a wide weight range.
Video Abstract: http://links.lww.com/QAD/A635
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Introduction
Whereas the use of effective combination antiretroviral
therapies (cARTs) has considerably reduced the preva-
lence of HIV-associated wasting, the prevalence of
overweight and obesity has increased among HIV-
infected individuals partly due to improved health [1–
6]. Obesity can alter the pharmacokinetics of drugs [7].
Consequently, standard drug doses may be insufficient in
heavy individuals. Suboptimal treatment response has
indeed been reported in a morbidly obese HIV-infected
patient treated with the standard 600 mg efavirenz (EFV)
dose [8]. Furthermore, EFV levels were shown to be
inversely correlated to body weight [9,10].
Obesity is also characterized by a chronic state of
inflammation with the release of pro-inflammatory or
immune-modulating factors [11]. The impact of over-
weight and obesity on the immune response in HIV
infection remains unclear. Studies from the pre-cARTera
found that overweight and obesity were associated with a
slower disease progression [12–14]. Conversely, in a more
recent study, overweight and obesity have been associated
with lower CD4þ recovery after cART initiation [15],
although this had not been consistently reported [16,17].
There are currently no comparisons of the virological and
immunological responses to initial EFV-containing
regimens in HIV-infected individuals across a wide range
of body weights. We hypothesized that heavy individuals
may be underdosed and, consequently, may have a less
vigorous virological response or be at risk for virological
failure or may have an inferior immune response to
treatment compared to normal-weight patients.
Methods
Study population
The Collaboration of Observational HIV Epidemiolo-
gical Research Europe (COHERE) includes 33 HIV
cohorts within the EuroCoord network (www.Euro-
Coord.net) [18].
All HIV-infected adults enrolled in COHERE and
starting an EFV-containing regimen were considered for
inclusion. Patients were excluded if their weight was
missing or if they did not have at least one viral load
measurement before and after EFV initiation. To limit
confounding, the analysis was limited to cART-naive
individuals.
Definitions
Weight, rather than BMI, was considered, as height was
not provided routinely by all cohorts. Analyses were
performed by stratifying weight into six groups defined
as: I (underweight) – below 55 kg; II (normal weight) –
at least 55, below 80 kg; III – at least 80, below 85 kg; IV
– at least 85, below 90 kg; V – at least 90, below 95 kg;
and VI – at least 95 kg. Baseline weight, CD4þ cell count,
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and viral load were selected as the most recent values prior
to EFV initiation.
Statistical methods
Kaplan–Meier plots were used to describe the time to
initial viral suppression after treatment initiation and the
time to subsequent virological rebound. Initial viral
suppression was defined as the first viral load 50 copies/
ml or less, and virological rebound was defined as the first
two consecutive viral load above 50 copies/ml. For
our primary analyses of virological rebound, treatment
switches were ignored. However, several sensitivity
analyses considered variations to this definition (see
below). Cox proportional-hazard regression analyses were
used to compare weight groups before and after adjustment
for sex, age, mode of HIVacquisition, ethnicity, hepatitis/
abnormal liver function test, pretreatment CD4þ cell
count and viral load, prior AIDS, nucleoside reverse
transcriptase inhibitor (NRTI) backbone, protease inhibi-
tor co-administration, cohort and calendar year.
Sensitivity analyses were performed to investigate the
robustness of the results to the way in which the
virological rebound endpoint was defined. In particular,
analyses were repeated after censoring each individual’s
follow-up on the date of EFV discontinuation, if this
occurred prior to virological rebound; the primary
analysis was repeated after including into the definition of
virological rebound individuals with one viral load above
50 copies/ml, who then changed their cART regimen
and discontinued EFV; the virological rebound definition
was modified to require two viral loads above 400 copies/
ml or 1000 copies/ml; and virological rebound was
defined as one viral load above 50 copies/ml.
Furthermore, analyses were performed after stratifying by
sex and ethnicity, with tests of interaction performed to
assess whether there were significant differences in the
associations between sex, white/non-white ethnicity, and
the weight groups.
The change in absolute CD4þ cell count during follow-
up was calculated as the difference between the CD4þ
values measured 6 and 12 months after EFV start and the
baseline value. The impact of weight on the CD4þ cell
count change 6 and 12 months after EFV start was
analyzed using multiple linear regression analyses adjusted
as described above. Statistical analyses were performed
using SAS version 9.13 (Cary, North Carolina, USA).
Results
Patient characteristics
In total, 19 968 individuals from 12 different cohorts were
included. The demographic and clinical characteristics of
the study population differed by weight categories
as described in Table 1. When looking at the weight
distribution in different calendar periods, the proportion
of heavier individuals was greater in more recent years
(Table 1, Supplementary Fig. 1, http://links.lww.com/
QAD/A625).
Virological response
Overall, 16 188 (81.1%) individuals achieved an
undetectable viral load after starting EFV. Adjusted
Cox regression analyses for the time to initial undetect-
able viral load showed that underweight individuals were
less likely to attain an undetectable viral load relative to
normal-weight individuals [relative hazard 0.91; 95%
confidence interval (CI) 0.86, 0.97; P¼ 0.004], whereas
no statistical difference was observed between heavier and
normal-weight groups (Table 2a, Supplementary Fig. 2a,
http://links.lww.com/QAD/A625).
Of the 16 188 patients attaining an undetectable viral
load, 5525 (34.1%) subsequently experienced viral load
rebound. Cumulative probability of virological rebound
was significantly higher for underweight compared to
normal-weight individuals (P¼ 0.0001, log-rank test)
(Supplementary Fig. 2b, http://links.lww.com/QAD/
A625). However, no significant differences were observed
among weight categories for the time to viral rebound in
adjusted Cox analyses (Table 2b). The results remained
consistent when repeating the analyses after censoring at
the time of EFV discontinuation or when using different
thresholds for viral rebound. Furthermore, no substantial
differences were seen in the associations between weight
group and either the time to initial viral suppression
or subsequent viral rebound when stratifying by sex or
ethnicity (all interaction P values >0.05).
Immunological response
The absolute CD4þ values 6 and 12 months after therapy
initiation were significantly higher with increasing weight
categories (Table 2c). In adjusted multivariable linear
regression analyses, the difference in absolute CD4þ cell
counts remained significant for the heaviest individuals
both at 6 [beta estimate 14.4, standard error (SE) 7.1,
P¼ 0.04] and 12 (beta estimate 17.2, SE 8.6, P¼ 0.05)
months (Table 2d). However, the CD4þ cell recovery was
comparable between heavier and normal-weight indi-
viduals.
Discussion
Overall, 22.7% of our study population fell in the heavy-
weight categories. The proportion of heavier individuals
tended to be greater in more recent years. Also, heavier
individuals were older, less likely to have acquired HIV
infection via intravenous drug user (IDU) or to have
AIDS prior to EFV start, more likely to have higher
baseline CD4þ values or to be treated with tenofo-
virþ emtricitabine. Collectively, these observations may
reflect calendar trends towards an earlier diagnosis and
Efavirenz treatment response and weight Marzolini et al. 195
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treatment with effective drugs [19,20]. Changes in
demographics may also be responsible for the observed
changes in weight distribution over the years. Consistent
with our observations, a recent analysis of the Swiss HIV
Cohort Study showed that increasing overweight and
obesity rates were explained by the aging of the HIV
population, fewer IDU, earlier treatment initiation, and
better cART coverage over the years [4].
We showed no difference in the virological response to
EFV-based therapy between heavy and normal-weight
individuals. Of note, the ability to detect differences may
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Table 2. Virological and immunological responses.
(a)
Weight (kg)
Median (months) Unadjusted Adjusted
RH (95% CI) P RH (95% CI) P
<55 4.8 0.90 (0.85, 0.95) 0.0002 0.91 (0.86, 0.97) 0.004
>55, <80 4.5 1 – 1 –
>80, <85 4.2 1.07 (1.01, 1.13) 0.02 1.05 (0.99, 1.11) 0.13
>85, <90 4.5 1.06 (0.99, 1.13) 0.09 1.00 (0.93, 1.07) 0.96
>90, <95 4.6 1.03 (0.95, 1.12) 0.51 0.98 (0.90, 1.07) 0.69
>95 4.2 1.10 (1.02, 1.19) 0.01 1.07 (0.99, 1.16) 0.09
(b)
Weight (kg) Unadjusted Adjusted
RH (95% CI) P RH (95% CI) P
<55 1.25 (1.15, 1.36) 0.0001 0.99 (0.90, 1.09) 0.78
>55, <80 1 – 1 –
>80, <85 0.86 (0.78, 0.95) 0.003 0.96 (0.86, 1.06) 0.38
>85, <90 0.81 (0.72, 0.92) 0.0008 0.99 (0.87, 1.13) 0.91
>90, <95 0.89 (0.77, 1.03) 0.13 1.06 (0.91, 1.24) 0.45
>95 0.86 (0.75, 0.99) 0.03 1.02 (0.88, 1.17) 0.84
(c)
6 months 12 months
Absolute value Increase from baseline Absolute value Increase from baseline
Weight (kg) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
<55 262 (124, 426) 99 (19, 190) 317 (166, 481) 139 (43, 239)
>55, <80 323 (134, 473) 88 (10, 179) 357 (163, 523) 120 (14, 233)
>80, <85 333 (115, 482) 80 (9, 180) 365 (154, 529) 104 (11, 230)
>85, <90 332 (73, 482) 87 (9, 181) 378 (103, 539) 120 (12, 231)
>90, <95 335 (47, 476) 70 (8, 173) 380 (87, 534) 111 (10, 230)
>95 340 (70, 485) 83 (8, 183) 390 (180, 520) 123 (17, 245)
P (Mann–Whitney) 0.0001 0.03 0.02 0.009
Overall 321 (129, 471) 88 (10, 180) 357 (160, 520) 121 (14, 234)
N¼12779 N¼12232 N¼11072 N¼10572
(d)
Weight (kg)
6 months 12 months
Beta (SE) P Beta (SE) P
<55 9.4 (5.3) 0.08 4.8 (6.6) 0.47
>55, <80 0 – 0 –
>80, <85 5.9 (5.1) 0.25 1.8 (6.2) 0.76
>85, <90 7.4 (6.2) 0.23 12.0 (7.6) 0.11
>90, <95 5.3 (7.7) 0.49 3.1 (9.6) 0.74
>95 14.4 (7.1) 0.04 17.2 (8.6) 0.05
Cox proportional-hazard regression analyses of associations between weight and the time to an initial undetectable viral load after treatment
initiation (a), and the time to subsequent viral load rebound after initial virological suppression (b), absolute CD4þ cell counts 6 and 12months after
efavirenz initiation (c) and beta estimates from adjusted multivariable linear regression analyses of factors associated with the absolute CD4þ cell
counts 6 and 12 months after efavirenz initiation. CI, confidence interval; IQR, interquartile range; N, total number; RH, relative hazard; SE,
standard error. Analyses were adjusted for demographic factors (sex, age, ethnicity); mode of HIV infection; cohort and calendar year; any hepatitis
or any abnormal liver function test; viral load; baseline CD4þ cell count; prior AIDS; and NRTI backbone and concomitant receipt of PI.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
have been limited by the small number of patients
weighting above 120 kg. EFV 900 mg once daily (q.d.)
has been shown to produce a similar exposure in
individuals weighting 100–120 kg than the exposure
obtained with the standard EFV 600 mg q.d. dosage in
normal-weight individuals [8]. Interestingly, EFV given at
400 mg q.d. has been shown to be noninferior to the
standard dose when combined with tenofovir and
emtricitabine in treatment-naı¨ve patients [21]. Thus,
one could speculate that the standard EFV dose has an
efficacy margin which is sufficient for a certain degree of
obesity. This efficacy margin may also result from the use of
more potent NRTI backbone in recent years [22]. In our
study, underweight individuals had a significantly longer
time to initial viral suppression compared to normal-
weight individuals. Of note, the proportion of individuals
infected through IDU and with AIDS prior to EFV
initiation was higher in the underweight category; thus
the longer time to initial suppression might be a
consequence of poorer adherence, later presentation, or
more advanced disease possibly resulting in drug malab-
sorption. However, there was no difference in the time to
viral rebound between these weight categories after adjust-
ment.
Obesity has been associated with the release of factors
which may impact the immune function [11]. Leptin has
notably been shown to promote T-cell proliferation and
activation in vitro [23,24]. Thus, heavy individuals might
have a different pattern of immune reconstitution. We
showed that heavier individuals had higher CD4þ cell
counts at baseline and after initiating EFV, whereas the
pattern of CD4þ recovery was comparable to normal-
weight individuals and within expected ranges [25]. The
observed higher baseline CD4þ values may reflect
calendar trends towards earlier diagnosis and treatment,
but could also be related to leptin-associated T-cell
proliferation. An increase in CD4þ cell counts has indeed
been described both in obese HIV-uninfected [26,27] and
HIV-infected populations [17,28]. Underweight indi-
viduals had lower baseline CD4þ values, but a higher
recovery compared to normal-weight individuals. Lower
CD4þ values at baseline could result from the underlying
malnutrition or a more advanced disease, whereas
younger age and higher nadir CD4þ cell count might
explain the higher recovery [29].
Despite previous reports of sex differences in EFV
exposure [30,31] and in leptin level [32,33], which was
shown to be inversely correlated to HIV replication [34],
our study did not find any sex difference in the association
with weight. Of note, the ability to detect a difference
may have been limited by the small number of women. In
addition, despite known ethnicity-related genetic differ-
ences in EFV metabolism [35], we did not find any
evidence that the association with weight differed by
ethnicity. Again, this could possibly result from the small
proportion of individuals of known black ethnicity.
Strengths of this study include the large size and the broad
geographical representation. However, this observational
study has limitations. Most cohorts do not measure levels of
EFV; therefore we could not correlate our observations to
drug concentrations. Data on EFV dosage were not
available; thus potential adjustments cannot be excluded.
The effect of adherence on treatment response couldnot be
assessed, although adherence patterns are not expected to
differ between heavy and normal-weight categories. The
number of individuals with extreme weights was low,
limiting any conclusions that could be drawn for severely
obese patients.
In conclusion, in this large European collaborative
study, virological and immunological responses to initial
EFV-containing regimens given at the standard 600 mg
dose were not impaired in heavy treatment-naive
individuals, suggesting that the standard dosage is
appropriate across a wide weight range. However, due
to the limited number of individuals weighting above
120 kg, response to EFV should be monitored carefully in
severely obese individuals.
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